These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21749857)

  • 1. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death.
    Singh KK; Shukla PC; Quan A; Lovren F; Pan Y; Wolfstadt JI; Gupta M; Al-Omran M; Leong-Poi H; Teoh H; Verma S
    Biochem Biophys Res Commun; 2011 Jul; 411(2):421-6. PubMed ID: 21749857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
    Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
    J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
    Fedele C; Riccio G; Malara AE; D'Alessio G; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jul; 134(2):595-602. PubMed ID: 22674190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
    Fedele C; Riccio G; Coppola C; Barbieri A; Monti MG; Arra C; Tocchetti CG; D'Alessio G; Maurea N; De Lorenzo C
    Breast Cancer Res Treat; 2012 Jun; 133(2):511-21. PubMed ID: 21947749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
    Grazette LP; Boecker W; Matsui T; Semigran M; Force TL; Hajjar RJ; Rosenzweig A
    J Am Coll Cardiol; 2004 Dec; 44(11):2231-8. PubMed ID: 15582322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.
    Shell SA; Lyass L; Trusk PB; Pry KJ; Wappel RL; Bacus SS
    Cell Cycle; 2008 Jun; 7(12):1769-75. PubMed ID: 18594201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
    Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
    Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction.
    Perry MC; Dufour CR; Eichner LJ; Tsang DW; Deblois G; Muller WJ; Giguère V
    Mol Cell Biol; 2014 Dec; 34(23):4232-43. PubMed ID: 25246633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase.
    Toth A; Nickson P; Qin LL; Erhardt P
    J Biol Chem; 2006 Feb; 281(6):3679-89. PubMed ID: 16339144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge.
    Tocchetti CG; Ragone G; Coppola C; Rea D; Piscopo G; Scala S; De Lorenzo C; Iaffaioli RV; Arra C; Maurea N
    Eur J Heart Fail; 2012 Feb; 14(2):130-7. PubMed ID: 22219501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways.
    Gordon LI; Burke MA; Singh AT; Prachand S; Lieberman ED; Sun L; Naik TJ; Prasad SV; Ardehali H
    J Biol Chem; 2009 Jan; 284(4):2080-7. PubMed ID: 19017630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Chan CT; Metz MZ; Kane SE
    Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Longva KE; Pedersen NM; Haslekås C; Stang E; Madshus IH
    Int J Cancer; 2005 Sep; 116(3):359-67. PubMed ID: 15800944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trastuzumab (Herceptin)].
    Tokuda Y; Suzuki Y; Saitou Y; Ohta M; Tajima T
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):645-52. PubMed ID: 11977556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways.
    Pugatsch T; Abedat S; Lotan C; Beeri R
    Breast Cancer Res; 2006; 8(4):R35. PubMed ID: 16839426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ErbB2/neuregulin signaling augments paclitaxel-induced cardiotoxicity in adult ventricular myocytes.
    Pentassuglia L; Timolati F; Seifriz F; Abudukadier K; Suter TM; Zuppinger C
    Exp Cell Res; 2007 May; 313(8):1588-601. PubMed ID: 17400210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.
    Fenouille N; Puissant A; Tichet M; Zimniak G; Abbe P; Mallavialle A; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S
    Oncogene; 2011 Dec; 30(49):4887-900. PubMed ID: 21685937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.